Xcout Intel
Oak Hill Bio
Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing rare disease drugs that have been deprioritized by other organizations. Formed in 2024 as a subsidiary of Oak Hill Bio Holdings, the company operates under the trading name OHB Pediatrics Ltd and is headquartered in Altrincham, United Kingdom.
Subscribe to see Oak Hill Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Oak Hill Bio at a glance
Oak Hill Bio is a biotechnology company headquartered in United States. It has raised at least $39M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $32.5M in June 2026. Xcout tracks 9 named people at Oak Hill Bio, including Josh Distler (Chief Executive Officer).
Oak Hill Bio leadership
- Josh DistlerChief Executive Officer
- Sharon MorrissChief Operating Officer
- Ike GreensteinChief Financial Officer
- Brenda VincenziChief Medical Officer
- Doug FambroughBoard Member
- Josh DistlerBoard Member
3 more named people on record for Oak Hill Bio, with roles, board committees and tenure — see the full roster →
Oak Hill Bio funding rounds
At least $39M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $32.5M | 4 named | |
| Series A | $6.5M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Oak Hill Bio competitors
A few of Oak Hill Bio's closest competitors — see the full list of competitors and alternatives →
Orchard Therapeutics plc is a biopharmaceutical company with operations including a U.S. headquarters located in Boston, Massachusetts.
Ollin Biosciences is a clinical-stage biopharmaceutical holding company established in 2023 and headquartered in Austin, Texas, dedicated to developing therapeutics.
Tempero Bio, Inc. is a clinical-stage biopharmaceutical holding company established in 2020 and headquartered in Oakland, California. The company focuses on developing transformative therapeutics and advancing its drug pipeline through clinical trials.
Healx is an AI-native pharmaceutical company that uses artificial intelligence and technology to discover and develop new treatments for rare diseases. The company redevelops, combines, and enhances known compounds to build a drug pipeline aimed at delivering effective therapies to patients.
Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary LentiVector platform technology facilitates the integration of genes into non-dividing cells, such as neurological cells in the brain and retinal cells in the eye, and can incorporate diverse therapeutic genes. The company's developmental pipeline includes promising candidates like Axo-Lenti-PD, a gene-based treatment for Parkinson's disease. Other pre-clinical stage programs feature OXB-302, targeting haematological tumors, and OXB-401, OXB-40X, and OXB-40Y, all addressing liver indications. Oxford Biomedica maintains numerous strategic alliances with prominent pharmaceutical entities such as Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and the Vaccines Manufacturing and Innovation Centre. Additionally, it engages in research collaborations, including a partnership with Circularis Biotechnologies to identify novel tissue-specific promoters for in vivo lentiviral gene therapy, Virica Biotech for scaling viral medicines, Isolere Bio for enhancing downstream manufacturing efficiencies of biologics, and BiologIC Technologies for utilizing a novel biocomputer system in viral vector development. Founded in 1995, Oxford Biomedica plc is headquartered in Oxford, United Kingdom.
Get Oak Hill Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Oak Hill Bio in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access